Standout Papers

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients wi... 2020 2026 2022 2024174
  1. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (2020)
    Xinan Sheng, Xieqiao Yan et al. Clinical Cancer Research

Immediate Impact

1 from Science/Nature 71 standout
Sub-graph 1 of 22

Citing Papers

Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
2025 Standout
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
2025 Standout
2 intermediate papers

Works of Weiqing Han being referenced

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
2020 Standout

Author Peers

Author Last Decade Papers Cites
Weiqing Han 133 157 155 23 355
Yoshimasa Oku 123 173 294 31 407
Khoon Leong Chuah 102 84 113 30 336
W. T. Knoefel 115 188 198 29 406
Cian Muldoon 219 243 88 31 402
Matthias Schauer 173 136 110 23 321
Yuichi Terado 123 69 104 27 352
Marit Ahrens 161 105 214 22 355
Akihito Nishio 83 169 133 18 373
Alison Y. Zhang 197 93 101 16 326
Shinya Maita 146 83 137 23 365

All Works

Loading papers...

Rankless by CCL
2026